Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

LATISSE 0.03% EYELASH SOLUTION

bimatoprost
$31.5025per ML
High Outlier

Strength

.3 mg/mL

Manufacturer

Allergan, Inc.

NDC

00023361605

Classification

Brand

Dosage Form

SOLUTION/ DROPS

Route

OPHTHALMIC

Last Updated

4/22/2026

Active Ingredients

BIMATOPROST

Approval Type

New Drug (NDA)

FDA Application

NDA022369

On Market Since

1/26/2009

Pharmacological Classes

Prostaglandin Analog
Prostaglandins

Price History

1W

0.0%

1M

+0.0%

3M

-0.0%

6M

+0.2%

1Y

+0.0%

3Y

+0.0%

5Y

+0.0%

All

-0.5%

Generic Alternatives

Save up to 32%

2 alternatives • Same active ingredient

BIMATOPROST 0.03% EYELASH SOLN
Generic
62332051105•Alembic Pharmaceuticals Inc.
$21.5284
Save 32%
LATISSE 0.03% EYELASH SOLUTION
Brand
00023361670•Allergan, Inc.
$40.9464
+30% more

Related Drugs

Same classification

ZIOPTAN 0.0015% EYE DROP
Brand
82584060930•Thea Pharma Inc.
$8.4919
per EA
CAVERJECT IMPULSE 10 MCG KIT
Brand
00009518101•Pharmacia & Upjohn Company LLC
$82.4905
per EA
TRAVATAN Z 0.004% EYE DROP
Brand
66758009556•Sandoz Inc.
$94.1791
per ML
TRAVATAN Z 0.004% EYE DROP
Brand
66758009575•Sandoz Inc.
$94.4384
per ML
CAVERJECT 20 MCG VIAL
Brand
00009370105•Pharmacia & Upjohn Company LLC
$95.7151
per EA
CAVERJECT IMPULSE 20 MCG KIT
Brand
00009518201•Pharmacia & Upjohn Company LLC
$106.3389
per EA
CAVERJECT 40 MCG VIAL
Brand
00009768604•Pharmacia & Upjohn Company LLC
$125.1112
per EA
EDEX 10 MCG CARTRIDGE 2-PK KIT
Brand
52244001002•Endo USA Inc.
$182.9167
per EA
EDEX 20 MCG CARTRIDGE 2-PK KIT
Brand
52244002002•Endo USA Inc.
$236.7563
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy